FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.
What happened
During a January 12 to 16, 2026 inspection, FDA found that Dabur gave investigators a falsified equipment logbook and that reported batch record and test-report values did not match source data. FDA also found missing microbiology plates, missing test records for multiple U.S.-marketed batches, inadequate cleaning validation on shared equipment, and no process validation for many OTC drug products. After a May 13, 2026 teleconference, Dabur recalled some products on June 2, 2026, and FDA placed all its drugs on Import Alert 66-40 (an FDA import refusal list) on June 5, 2026.
What FDA found
The quality control unit (the group responsible for quality decisions) did not have or use the authority to approve or reject materials and products and to review production records, and FDA found a falsified equipment logbook and reported values that did not match source data.
21 CFR 211.22(a)Laboratory records were incomplete: microbiology and media plates recorded as incubated were missing, and test procedures or data could not be produced for multiple U.S.-marketed batches.
21 CFR 211.194(a)Cleaning and maintenance procedures were inadequate because cleaning was checked only by looking, with no proven carryover limits, residue testing, or surface sampling, and one shared line had no cleaning validation.
21 CFR 211.67(b)Production and process control procedures were inadequate because the firm had not validated (shown to consistently work) manufacturing processes for most OTC drug products.
21 CFR 211.100(a)
What FDA wants
FDA asks Dabur to respond in writing within 15 working days with corrective actions and comprehensive assessments: documentation systems, quality-unit authority, data-integrity investigation, cleaning cross-contamination risk, and process validation plans and timelines. FDA also recommends an independent qualified consultant and may withhold approvals or refuse imports until corrections are confirmed.
Who should pay attention
- U.S. distributors and retailers selling Dabur OTC drugs
- contract manufacturers making multiple OTC products on shared equipment
- quality and regulatory teams that rely on supplier lab records
This is a summary. Read the original letter on fda.gov.